alexa Human Papillomavirus (HPV) Vaccine: Is it worthwhile? | OMICS International | Abstract
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Editorial

Human Papillomavirus (HPV) Vaccine: Is it worthwhile?

Marlene F Shehata* and Alan Pater

Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa ON, Canada

Corresponding Author:
Marlene Shehata R.Ph., BSc. Pharm., MSc. Med., PC., PhD
Clinical Pharmacist Consultant/Cardiovascular Geneticist
Ottawa ON, Canada
Tel: 519-702-5476
Fax: 347-710-5334
E-mail: [email protected]

Received date: June 22, 2011; Accepted date: June 22, 2011; Published date: July 22, 2011

Citation: Shehata MF, Pater A (2011) Human Papillomavirus (HPV) Vaccine: Is it worthwhile?. J Biotechnol Biomaterial 1:103e. doi:10.4172/2155-952X.1000103e

Copyright: © 2011 Shehata MF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Cervical cancer is one of the most common cancers in women. Human Papillomavirus (HPV) is the primary cause of cervical, anal, vulvar, vaginal and penile cancers as well as genital warts. Over 120 types of HPV have been isolated with more than 40 of these types infecting the epithelial lining of the anal and genital tracts [6]. HPV infections can be currently screened using the Pap cytology and the HPV DNA testing [7]. False positive Pap tests can greatly impact the patient’s psychological status and is currently costing over $ 244 M/year [10]. Given the huge economic burden associated with Pap cytology and DNA testing, the purpose of this editorial is to discuss the value of HPV vaccines in preventing HPV infections and hence reducing the economic burden of HPV diagnostic testing.

Recommended Conferences

International Conference on Biotechnology and Healthcare

Auckland, New Zealand
Share This Page
Top